

# Pfizer Pipeline | Key Anticipated 2026 Catalysts

Updated: June 22, 2026

## Regulatory Decisions

- **HYMPAVZI (marstacimab)**  
Hemophilia A/B with Inhibitors (BASIS)
- **PADCEV (enfortumab vedotin)<sup>1,2</sup>**  
Cisplatin-ineligible Muscle-invasive Bladder Cancer (EV-303)
- PADCEV (enfortumab vedotin)<sup>2</sup>**  
Cisplatin-eligible Muscle-invasive Bladder Cancer (EV-304)
- TUKYSA (tucatinib)**  
1L HER2+ Metastatic Breast Cancer Maintenance (HER2CLIMB-05)

- Approved
- Not approved

## Data Readouts

- **Berobenatide (PF'3944)**  
Monthly Chronic Weight Management (VESPER-3) | Phase 2b
- Berobenatide + Amylin Analog\* (PF'3945 / MET-233i) Combo**  
Chronic Weight Management | Phase 1/2
- **ELREXFIO (elranatamab)**  
Double-class Exposed Relapsed / Refractory Multiple Myeloma (MagnetisMM-5)
- LITFULO (ritlecitinib)**  
Vitiligo (TRANQUILLO)
- **Lyme Disease Vaccine Candidate (PF-07307405)<sup>3</sup>**  
Lyme Disease Infection (VALOR)
- Mevrometostat (PF-06821497)**  
1-2L Metastatic Castration-resistant Prostate Cancer Post-abiraterone (MEVPRO-1)
- **Sigvotatug vedotin (PF-08046047)**  
2L+ Non-squamous Metastatic Non-small Cell Lung Cancer (Be6A LUNG-01)
- **TALZENNA (talazoparib) + XTANDI (enzalutamide)**  
1L HRRm Metastatic Castration-sensitive Prostate Cancer (TALAPRO-3)

- Achieved
- No longer anticipated in 2026

## Pivotal Study Starts

- **Berobenatide (PF'3944)\*\***  
10 Studies
- HYMPAVZI (marstacimab)**  
Moderate Hemophilia A/B
- LITFULO (ritlecitinib)**  
Moderate Alopecia Areata
- NURTEC (rimegepant)**  
Chronic Migraine
- NURTEC (rimegepant)**  
Redosing (Acute Treatment of Migraine)
- **PADCEV (enfortumab vedotin)<sup>2</sup>**  
Muscle-invasive Bladder Cancer (Bladder Sparing) (EV-309)
- **PCV25 (PF-07872412)**  
Pneumococcal Infection\*\*\*
- **PD-1xVEGF (PF'4404)<sup>1</sup>**  
1L Metastatic Colorectal Cancer (Symbiotic-GI-03)
- PD-1xVEGF (PF'4404)**  
1L Endometrial Cancer
- **PD-1xVEGF (PF'4404)**  
1L Squamous / Non-squamous Non-small Cell Lung Cancer (Symbiotic-Lung-01)
- PD-1xVEGF (PF'4404) + PADCEV (enfortumab vedotin)<sup>2</sup>**  
1L Metastatic Urothelial Cancer
- Sigvotatug vedotin (PF-08046047)**  
1L Non-small Cell Lung Cancer TPS All Comers

- Study started
- Study discontinued / start no longer anticipated in 2026

1. Achieved in late 2025 | 2. Pfizer and Astellas have a collaboration agreement to co-develop PADCEV® | 3. Pfizer and Valneva have a collaboration agreement to co-develop PF-07307405

\*With dual amylin and calcitonin receptor activity | \*\*Includes VESPER-4 study of berobenatide for weekly chronic weight management in participants with obesity or overweight and without type 2 diabetes mellitus (started late 2025), VESPER-5 study of berobenatide for weekly chronic weight management in participants with obesity or overweight and type 2 diabetes mellitus (started March 2026), VESPER-6 study of berobenatide for monthly chronic weight management, study of switch from approved weekly injectables to monthly berobenatide, study of berobenatide in obstructive sleep apnea, study of berobenatide in knee osteoarthritis, study of berobenatide in China, study of berobenatide in Japan, and two additional studies of berobenatide | \*\*\*25-valent pediatric vaccine candidate

1L=First-line; 1-2L=First- or second-line; 2L+=Second-line plus; HER2=human epidermal growth factor receptor 2; HRRm=Homologous recombination repair mutant; PD-1=programmed cell death protein-1; TPS=Tumor proportion score; VEGF=vascular endothelial growth factor

This list is not inclusive of all ongoing programs in Pfizer's product pipeline and inclusion in this list does not guarantee continued investment. Milestone descriptions are intended to be high-level and may present disease area rather than indication. Data readouts are Phase 3 unless otherwise noted. Listed pivotal studies may include those that are Phase 3, Phase 4, or potentially registration-enabling Phase 2 or 2/3 studies. Some pivotal study starts, which are defined by first subject first dose (FSFD), may be subject, among other things, to data generation in earlier-stage studies and/or alignment with development partners and regulatory agencies. Many clinical research studies are event driven and readouts are therefore subject to change. Pfizer assumes no obligation to update this information in response to new or future developments. Please see Pfizer's SEC filings, press releases and other disclosures for additional information.

